RUNX1表达中度减弱时反而增强急性髓系白血病白血病生成
本研究探讨RUNX1在急性髓系白血病中的双向作用,发现RUNX1中等表达水平的患者预后最差,中度减弱RUNX1通过上调RUNX2/RUNX3总RUNX表达、增强GSTA2转录激活而加速细胞周期进程,促进白血病细胞增殖;依他尼酸抑制GSTA2可延长AML小鼠生存。
要点
- RUNX1中等表达水平与AML患者最差预后相关。
- 中度减弱RUNX1通过加速细胞周期进程促进AML细胞增殖,而深度耗竭导致细胞周期阻滞和凋亡。
- 依他尼酸抑制GSTA2可延长AML小鼠生存。
核心结论
- 中度减弱RUNX1表达通过GSTA2介导的细胞内环境改变反而增强AML细胞的白血病生成,GSTA2可能成为抗白血病策略的新治疗靶点。
研究设计与样本
- 研究纳入AML患者临床数据进行分析,并进行一系列不同RUNX1减弱程度的RUNX1敲低实验及AML小鼠体内实验。
主要发现
- 临床数据显示RUNX1中等水平基因表达标记AML患者中预后最差的队列。
- 中度减弱RUNX1通过加速细胞周期进程促进AML细胞传播,而深度RUNX1耗竭导致细胞周期阻滞和凋亡。
- 在RUNX1沉默的肿瘤中,RUNX2和RUNX3的代偿性上调量大致相当,使RUNX1中度减弱的AML细胞中总RUNX表达水平绝对升高。
- 总RUNX升高增强GSTA2表达的转录激活,GSTA2处理细胞内活性氧的分解代谢并推进细胞周期进程,最终使RUNX1中度减弱的AML细胞获得增殖优势。
- 依他尼酸治疗延长了AML小鼠的体内生存。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Besides being a classical tumor suppressor, runt-related transcription factor 1 (RUNX1) is now widely recognized for its oncogenic role in the development of acute myeloid leukemia (AML). Here we report that this bidirectional function of RUNX1 possibly arises from the total level of RUNX family expressions. Indeed, analysis of clinical data revealed that intermediate-level gene expression of RUNX1 marked the poorest-prognostic cohort in relation to AML patients with high- or low-level RUNX1 expressions. Through a series of RUNX1 knockdown experiments with various RUNX1 attenuation potentials, we found that moderate attenuation of RUNX1 contributed to the enhanced propagation of AML cells through accelerated cell-cycle progression, whereas profound RUNX1 depletion led to cell-cycle arrest and apoptosis. In these RUNX1-silenced tumors, amounts of compensative upregulation of RUNX2 and RUNX3 expressions were roughly equivalent and created an absolute elevation of total RUNX (RUNX1 + RUNX2 + RUNX3) expression levels in RUNX1 moderately attenuated AML cells. This elevation resulted in enhanced transactivation of glutathione S-transferase α 2 (GSTA2) expression, a vital enzyme handling the catabolization of intracellular reactive oxygen species (ROS) as well as advancing the cell-cycle progressions, and thus ultimately led to the acquisition of proliferative advantage in RUNX1 moderately attenuated AML cells. Besides, treatment with ethacrynic acid, which is known for its GSTA inhibiting property, actually prolonged the survival of AML mice in vivo. Collectively, our findings indicate that moderately attenuated RUNX1 expressions paradoxically enhance leukemogenesis in AML cells through intracellular environmental change via GSTA2, which could be a novel therapeutic target in antileukemia strategy.
引用
- Morita K, Maeda S, Suzuki K, et al. Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately attenuated RUNX1 expressions. Blood Adv. 2017. PMID: 29296785. doi:10.1182/bloodadvances.2017007591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。